AdAlta Limited (ASX:1AD) has progressed its ‘East to West’ cellular immunotherapy strategy by securing its first CAR-T asset, advancing Australian manufacturing and US FDA regulatory engagement, while raising A$5.3 million in FY2026 and reporting a net loss of $4.68 million.
- Secured EW-001 CAR-T therapy rights and commenced Australian manufacturing transfer
- Reported promising clinical data with up to 50% response in advanced mesothelioma
- Raised approximately A$5.3 million across three placements
- Progressed partnering and patent protection for protein therapeutics AD-214 and WD-34
- Board changes with appointment of Fadi Diab and resignation of David Fuller
First Cellular Immunotherapy Asset Secured Under ‘East to West’ Strategy
AdAlta Limited (ASX:1AD) has taken a significant step in executing its novel ‘East to West’ strategy by securing EW-001, a first-in-class armoured CAR-T therapy targeting mesothelin (MSLN) for advanced mesothelioma and other solid cancers. The development and collaboration agreement with Shanghai Cell Therapy Group Co Ltd (SHcell) grants AdAlta rights to develop EW-001 outside Greater China, unlocking proprietary materials and clinical data essential for Australian manufacturing.
EW-001 distinguishes itself by secreting PD1-blocking molecules to overcome tumour immune suppression, a mechanism that has yielded up to a 50% overall response rate and a 20% complete response rate in investigator-initiated trials in China, outcomes rarely seen in advanced mesothelioma. These encouraging results position EW-001 as a potentially transformative treatment in a market forecast to reach US$12.2 billion by 2034, with AdAlta’s addressable opportunity estimated at US$4.2 billion before expansion into other cancers.
Australian Manufacturing and Regulatory Pathway Progress
Recognising manufacturing as a critical value driver for CAR-T therapies, AdAlta has commenced technology transfer of EW-001 to Cell Therapies Pty Ltd (CTPL) in Australia. The process benefits from a shorter manufacturing time of under two days and avoids costly viral vectors, with CTPL poised to become the global manufacturing reference site.
Complementing this, AdAlta has engaged DarkHorse Consulting to advise on US FDA regulatory strategy and formed an EW-001 Clinical Advisory Board comprising senior Australian CAR-T clinicians. A pre-IND meeting with the FDA is anticipated in the second half of 2026, marking a key milestone towards Western regulatory approval and clinical trials.
Expanding Pipeline and AI-Driven Asset Selection
AdAlta aims to replicate the EW-001 model by in-licensing additional clinical-stage T cell therapies from Asia and advancing them through Australian manufacturing and US regulatory pathways. The company is actively due diligencing further assets, targeting one new clinical candidate annually, supported by its AI screening agent EMU and a new collaboration with Oktopi, which provides AI-enabled peer review of development plans.
Progress on Protein Therapeutics and Intellectual Property
Beyond cell therapies, AdAlta is advancing its proprietary i-body® platform assets. AD-214, a Phase 2-ready fusion protein targeting fibrotic diseases such as IPF and kidney fibrosis, has secured patent protection across key markets including a recent Canadian patent grant. The company is pursuing partnerships and potential spin-out financing, with growing interest in kidney fibrosis indications.
WD-34, an i-body® discovery targeting malaria parasite invasion, remains at the preclinical stage with ongoing efforts to secure funding and optimise the candidate. Patent applications have been filed to protect this asset’s broad-spectrum potential.
Financials, Capital Raising and Governance Updates
For FY2026, AdAlta reported a net loss of $4.68 million, slightly higher than the prior year, reflecting increased R&D investment including a US$2 million milestone payment to SHcell. The company raised approximately A$5.3 million through three placements, supporting milestone payments, manufacturing scale-up, and regulatory engagement.
Cash at year-end stood at $1.28 million, with the Group maintaining a lean headcount of two permanent employees supplemented by consultants. Board composition changed with the appointment of Mr Fadi Diab as Non-executive Director in March 2026 and the retirement of Dr David Fuller in April 2026.
Risks and Uncertainties Remain
AdAlta’s report candidly outlines risks including regulatory hurdles, clinical trial uncertainties, funding dependencies, intellectual property challenges, and competitive pressures. Notably, proposed changes to Australia’s R&D Tax Incentive program could materially affect future cash flows. The company remains reliant on successful capital raises and partnering transactions to advance its programs.
Post year-end developments include a strategic collaboration with Oktopi to enhance R&D decision-making through AI and a share issuance raising $9.45 million, reflecting ongoing efforts to bolster financial resources.
Bottom Line?
AdAlta’s FY2026 progress validates its ‘East to West’ model, but execution risks and funding needs underscore the importance of upcoming clinical and regulatory milestones.
Questions in the middle?
- Will the upcoming US FDA pre-IND meeting confirm a clear regulatory pathway for EW-001?
- How rapidly can AdAlta expand its cellular immunotherapy pipeline beyond EW-001?
- What impact will proposed changes to Australia’s R&D tax incentives have on AdAlta’s funding strategy?